PCSK9 inhibition in patients with heart transplantation: A case series

Area of Science:

• Cardiology
• Pharmacology
• Transplant Medicine

Background:

• Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a class of lipid-lowering drugs.
• Limited data exist on the safety and efficacy of PCSK9 inhibitors in cardiac transplant patients.

Observation:

• This case series examines three cardiac transplant patients who received PCSK9 inhibitors.
• The study focuses on the impact of PCSK9 inhibitors on low-density lipoprotein cholesterol levels and patient safety.

Findings:

• PCSK9 inhibitors demonstrated significant low-density lipoprotein cholesterol reduction in cardiac transplant recipients.
• Short-term administration of PCSK9 inhibitors was found to be safe in this patient cohort.

Implications:

• These findings suggest PCSK9 inhibitors may be a viable treatment option for managing hyperlipidemia in cardiac transplant patients.
• Further research is warranted to confirm long-term safety and efficacy.